Cover Image

Sacituzumab govitecan: past, present and future of a new antibody-drug conjugate and future horizon: drug evaluation

Sacituzumab govitecan (SG) is a new antibody-drug conjugate directed against the cell-surface antigen Trop-2. Characteristics of the linker connecting the payload SN-38 to the antibody allows SG to kill tumor cells expressing Trop-2 and also the adjacent tumor cells (bystander effect). SG showed eff...

Full description

Saved in:
Bibliographic Details
Main Authors: Furlanetto, Jenny (Author) , Marmé, Frederik (Author) , Loibl, Sibylle (Author)
Format: Article (Journal)
Language:English
Published: 7 Sep 2022
In: Future oncology
Year: 2022, Volume: 18, Issue: 28, Pages: 3199-3215
ISSN:1744-8301
DOI:10.2217/fon-2022-0407
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.2217/fon-2022-0407
Verlag, lizenzpflichtig, Volltext: http://www.futuremedicine.com/doi/10.2217/fon-2022-0407
Get full text
Author Notes:Jenny Furlanetto, Frederik Marmé and Sibylle Loibl
Description
Summary:Sacituzumab govitecan (SG) is a new antibody-drug conjugate directed against the cell-surface antigen Trop-2. Characteristics of the linker connecting the payload SN-38 to the antibody allows SG to kill tumor cells expressing Trop-2 and also the adjacent tumor cells (bystander effect). SG showed efficacy and safety in several epithelial tumors. The phase III ASCENT trial led to the approval of SG (10 mg/kg, d1,8 q3w) in patients with advanced or metastatic triple-negative breast cancer (TNBC) who have received ≥2 prior systemic therapies, including ≥1 for metastatic disease. The phase III TROPiCS-02 trial in heavily pretreated advanced hormone receptor (HR)-positive breast cancer has recently shown an improvement in progression-free survival for patients treated with SG compared to single-agent chemotherapy. The phase III post-neoadjuvant SASCIA study in early high-risk TNBC and HR-positive breast cancer is currently recruiting patients.
Item Description:Gesehen am 19.09.2023
Physical Description:Online Resource
ISSN:1744-8301
DOI:10.2217/fon-2022-0407

Similar Items